4D Molecular Therapeutics, Inc. FDMT
NASDAQ · United States · Health Technology
$13.65-0.20 (-1.41%)
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Investing.com -- B. Riley Securities reiterated its Buy rating and $37 price target on 4D Molecular Therapeutics, citing the launch of a Phase 3 trial in diabetic macular edema and encouraging two-year data for its lead gene therapy candidate.
OCUL’s selloff on Monday was spurred by clinical updates from competitors on their wet AMD treatments.
4D-150 is advancing into Phase 3 development for DME, a second multi-billion-dollar retinal disease market with significant unmet need First patients have been enrolled in 4SIGHT global Phase 3 trial (N=514) evaluating 4D-150 in a treatment-naïve DME populationUpdated 2-year data from SPECTRA Part 1 clinical trial in DME continue to demonstrate a favorable safety profile, durable vision and anatomic improvements and clinically meaningful treatment burden reduction EMERYVILLE, Calif., Sept. 28, 2
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.